Pfizer Corporation

Mary Theresa Didiuk

Angel Guzman-Perez

Meihua Mike Tu

Jeffrey Allen Pfefferkorn

Kevin James Filipski

Benjamin Dawson Stevens

David Andrew Griffith

Gary Erik Aspnes

Robert L Dow

Esther Cheng Yin Lee

Esther C Lee

Erin M Duffy

Daniel Patrick Walker

Ravi Shanker Garigipati

Benjamin C Stevens

Kevin K Liu

Wan F Lau

Feng C Bi

Roberto Colon-Cruz

Wayne S McDonald

Esther Cheng Lee

The invention provides a compound of Formula (1) or a pharmaceutically acceptable salt of the compound, wherein R, R, R, Z, A, L and Aare as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R, R, R, Z, A, L and Aare as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R, R, R, A, A, A, A, L, B, B, Band Bare as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Glucagon receptor modulators

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R, R, A, A, A, B, B, Band Bare as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Quinolinyl glucagon receptor modulators

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R, R, A, A, A, B, B, Band Bare as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon. 

The invention provides a compound of Formula (I) Z N N O N O A1R2 R1 R3R 3 L A2 (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3,Z, A1, L and A 5 2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal. 

Growing community of inventors

Madison, CT, United States of America

Mary Theresa Didiuk